Atwood & Palmer’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7K Hold
100
﹤0.01% 388
2026
Q1
$5.08K Hold
100
﹤0.01% 408
2025
Q4
$2.95K Hold
100
﹤0.01% 432
2025
Q3
$2.58K Hold
100
﹤0.01% 438
2025
Q2
$2.76K Hold
100
﹤0.01% 457
2025
Q1
$2.83K Hold
100
﹤0.01% 384
2024
Q4
$4.16K Sell
100
-400
-80% -$19.1K ﹤0.01% 388
2024
Q3
$33.4K Hold
500
﹤0.01% 254
2024
Q2
$59.4K Hold
500
﹤0.01% 216
2024
Q1
$53.3K Hold
500
﹤0.01% 208
2023
Q4
$49.7K Sell
500
-1
-0.2% -$84 ﹤0.01% 218
2023
Q3
$51.7K Buy
501
+1
+0.2% +$112 ﹤0.01% 211
2023
Q2
$60.8K Hold
500
0.01% 213
2023
Q1
$76.8K Sell
500
-1,000
-67% -$165K 0.01% 186
2022
Q4
$269K Buy
1,500
+1,100
+275% +$180K 0.02% 132
2022
Q3
$47K Hold
400
﹤0.01% 203
2022
Q2
$57K Hold
400
0.01% 199
2022
Q1
$69K Sell
400
-400
-50% -$67.3K 0.01% 202
2021
Q4
$203K Sell
800
-50
-6% -$14.6K 0.02% 149
2021
Q3
$327K Hold
850
0.03% 127
2021
Q2
$200K Hold
850
0.02% 148
2021
Q1
$111K Hold
850
0.01% 174
2020
Q4
$89K Buy
850
+50
+6% +$5.06K 0.01% 178
2020
Q3
$57K Buy
+800
New +$55.8K 0.01% 182

Other funds holding MRNA

Atwood & Palmer's MRNA Position: Q2 2026 in Review

Atwood & Palmer held its Moderna (MRNA) position steady in Q2 2026 at 100 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #388.

Atwood & Palmer first reported a position in MRNA in Q3 2020 and has held it in 24 quarters since. The position peaked at $327K in Q3 2021. 184 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Atwood & Palmer held 100 shares of Moderna worth $7K as of Q2 2026.
  • Atwood & Palmer left its Moderna share count unchanged in Q2 2026.
  • Moderna made up ﹤0.01% of Atwood & Palmer's portfolio in Q2 2026, its #388 holding.
  • Atwood & Palmer first reported a position in Moderna in Q3 2020 and has held it in 24 quarters since.
  • Atwood & Palmer's Moderna position peaked at $327K in Q3 2021.
  • 184 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Atwood & Palmer's 13F filing for Q2 2026, filed 8 Jul 2026.